Monitor the ASGCT presentation on May 14 for full data. Early signs of activity without preconditioning could de-risk the program, but sample is too small to draw conclusions. Expect volatility around the event.
Price Chart
Executive Summary
Cabaletta Bio announced it will present new clinical and translational data from 4 refractory patients treated with rese-cel without preconditioning in the RESET-PV trial at ASGCT 2026. The data showed biologic activity in 2 of 4 patients and a favorable safety profile, but the sample is small and early-stage. No financial impact or guidance changes were disclosed.
Key Facts
- Data from 4 refractory pemphigus vulgaris patients receiving lowest-dose rese-cel without preconditioning will be presented at ASGCT on May 14, 2026.
- 2 of 4 patients demonstrated compelling clinical activity through 6 months; 3 of 4 remained off all immunomodulators and steroids.
- Complete peripheral B cell elimination observed in 3 of 4 patients; one Grade 1 CRS, no ICANS.
- Higher dose cohort in RESET-PV has been enrolled; durability data expected in H2 2026.
- Initial dose cohort of RESET-SLE (lupus) is fully enrolled; initial data expected in H1 2026.
Financial Impact
No financial figures disclosed; pre-revenue biotech.
Risk Factors
- Small sample size (n=4) limits statistical reliability.
- Early-stage data may not replicate in larger cohorts.
- No financial data or guidance provided; stock may move on sentiment alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-202389 |
| Document: 0001193125-26-202389-index-headers.html | 0001193125-26-202389 |
| Document: 0001193125-26-202389-index.html | 0001193125-26-202389 |
| Document: 0001193125-26-202389.txt | 0001193125-26-202389 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $2.91 $2.46 | ▼ −15.46% | ▼ −15.57% | $1.91 (−34.36%) |
Aug 15, 2026 6w ago | Institutional Cluster | $2.89 $3.10 | ▲ +7.27% | ▲ +8.46% | $1.91 (−33.91%) |
Aug 13, 2026 7w ago | 8-K | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Aug 13, 2026 7w ago | Press Release | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.01 $2.84 | ▼ −5.65% | ▼ −6.32% | $1.91 (−36.54%) |
Jun 3, 2026 17w ago | 8-K | $3.58 $3.04 | ▼ −15.08% | ▼ −11.26% | $1.91 (−46.65%) |
Jun 1, 2026 17w ago | DEFA14A | $3.67 $3.25 | ▼ −11.44% | ▼ −8.69% | $1.91 (−47.96%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▼ −2.22% | ▼ −2.93% | $1.91 (+47.09%) |
May 14, 2026 20w ago | Press Release | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access